L-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: A novel series of potent calcium-sensing receptor antagonists

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2250-2263

  Widler, Leo ^a   Altmann, Eva ^a   Beerli, René ^a   Breitenstein, Werner ^a   Bouhelal, Rochdi ^a   Buhl, Thomas ^a   Gamse, Rainer ^a   Gerspacher, Marc ^a   Halleux, Christine ^a   John, Markus R ^a   Lehmann, Hansjoerg ^a   Kalb, Oskar ^a   Kneissel, Michaela ^a   Missbach, Martin ^a   Müller, Irene R ^a   Reidemeister, Sibylle ^a   Renaud, Johanne ^a   Taillardat, Agnes ^a   Tommasi, Ruben ^b   Weiler, Sven ^a   Wolf, Romain M ^a   Seuwen, Klaus ^a   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 4 PHENYL 6 ALKOXY 1H QUINAZOLIN 2 ONE; CALCIMIMETIC AGENT; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG POTENCY; DRUG SOLUBILITY; EXPERIMENTAL DOG; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PARATHYROID HORMONE RELEASE; RAT; SCREENING; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; DOG; DRUG ANTAGONISM; GENETICS; IC 50; METABOLISM; ORAL DRUG ADMINISTRATION; SECRETION; SYNTHESIS; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BONE DENSITY CONSERVATION AGENTS; DOGS; INHIBITORY CONCENTRATION 50; MALE; PARATHYROID HORMONE; QUINAZOLINONES; RATS; RATS, WISTAR; RECEPTORS, CALCIUM-SENSING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949412227     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901811v     Document Type: Article

References (59)

1. Bodenner, D.; Redmann, C.; Riggs, A. Teriparatide in the management of osteoporosis. Clin. Interventions Aging 2007, 2, 499-507.
2. Bilezikian, J. P. Anabolic therapy for osteoporosis. Women's Health 2007, 3, 243-253.
3. Girotra, M.; Rubin, M. R.; Bilezikian, J. P. The use of parathyroid hormone in the treatment of osteoporosis. Rev. Endocrinol. Metab. Disord. 2006, 7, 113-121.
4. Rubin, M. R.; Bilezikian, J. P. Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005, 65 (17), 2481-2498.
5. Rubin, M. R.; Cosman, F.; Lindsay, R.; Bilezikan, J. P. The anabolic effects of parathyroid hormone. Osteoporosis Int. 2002, 13, 267-277.
6. Compston, J. Recombinant parathyroid hormone in the management of osteoporosis. Calcif. Tissue Int. 2005, 77 (2), 65-71.
7. Eriksen, E. F.; Robins, D. A. Teriparatide: abone formation treatment for osteoporosis. Drugs Today 2004, 40, 935-948.
8. Hodsman, A. B.; Bauer, D. C.; Dempster, D. W.; Dian, L.; Hanley, D. A.; Harris, S. T.; Kendler, D. L.; McClung, M. R.; Miller, P. D.; Olszynski, W. P.; Orwoll, E.; Yuen, C. K. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 2005, 26 (5), 688-703.
9. Hodsman, A. B.; Hanley, D. A.; Ettinger, M. P.; Bolognese, M. A.; Fox, J.; Metcalfe, A. J.; Lindsay, R. Efficacy and safety of human parathyroid hormone-(l -84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 2003, 88 (11), 5212-5220.
10. Trivedi, R.; Mithal, A.; Chattopadhyay, N. Recent updates on the calcium-sensing receptor as a drug target. Curr. Med. Chem. 2008, 15 (2), 178-186.
11. Brown, E. M. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell. Biochem. 2007, 45, 139-165.
12. Brown, E. M.; MacLeod, R. J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81, 239-297.
13. 2+ and other ions as extracellular (first) messengers. Physiol. Rev. 1991, 71, 371-411.
14. Nemeth, E. F. Calcium receptor-dependent regulation of cellular functions. News Physiol. Sci. 1995, 10, 1-5.
15. Steddon, S. J.; Cunningham, J. Calcimimetics and calcilytics-fooling the calcium receptor. Lancet 2005, 365 (9478), 2237-2239.
16. Jensen, A. A.; Brauner-Osbome, H. Allosteric modulation of the calcium-sensing receptor. Curr. Neuropharmacol. 2007, 5 (3), 180-186.
17. Dobnig, H.; Turner, R. T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138 (11), 4607-4612.
18. Frolik, C. A.; Black, E. C.; Cain, R. L.; Satterwhite, J. H.; Brown-Augsburger, P. L.; Sata, M.; Hock, J. M. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 2003, 33, 372-379.
19. Onyia, J. E.; Helvering, L. M.; Gelbert, L.; Wei, T.; Huang, S.; Chen, P.; Dow, E. R.; Maran, A.; Zhang, M.; Lotinun, S.; Lin, X.; Halladay, D. L.; Miles, R. R.; Kulkami, N. H.; Ambrose, E. M.; Ma, Y. L.; Frolik, C. A.; Sato, M.; Bryant, H. U.; Turner, R. T. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis of DNA microarray. J. Cell. Biochem. 2005, 95, 403-418.
20. Messa, P.; Alfieri, C.; Brezzi, B. Cinacalcet: pharmacological and clinical aspects. Expert Opin. Drug Metabol. Toxicol. 2008, 4 (12), 1551-1560.
21. 2+-receptor. Dtsch. Med. Wochenschr. 2008, 133 (33), 1681-1683.
22. Harrington, P.; Fotsch, C. Calcium sensing receptor activators: Calcimimetics. Curr. Med. Chem. 2007, 14 (28), 3027-3034.
23. Marquis, R. W.; Lago, A. M.; Callahan, J. F.; Lee Trout, R. E.; Gowen, M.; DelMar, E. G.; Van Wagenen, B. C.; Logan, S.; Shimizu, S.; Fox, J.; Nemeth, E. F.; Yang, Z.; Roethke, T.; Smith, B. R.; Ward, K. W.; Lee, J.; Keenan, R. M.; Bhatnagar, P. Antagonists of the Calcium Receptor I. Amino Alcohol-Based Parathyroid Hormone Secretagogues. J. Med. Chem. 2009, 52 (13), 3982-3993.
24. Gowen, M.; Stroup, G. B.; Dodds, R. A.; James, I. E.; Votta, B. J.; Smith, B. R.; Bhatnagar, P. K.; Lago, A. M.; Callahan, J. F.; DelMar, E. G.; Miller, M. A.; Nemeth, E. F.; Fox, J. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. 2000, 105 (11), 1595-1604.
25. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 2001, 299 (1), 323-331.
26. Nemeth, E. F. The search for calcium receptor antagonists (calcilytics). J. Mol. Endocrinol. 2002, 29 (1), 15-21.
27. Doggrell, S. A.; Del Fresno, M.; Castaner, J. NPS - 2143. Drugs Future 2002, 27(2), 140-142.
28. Marquis, R. W.; Ramanjulu, J. M.; Casillas, L. N. Preparation of acyloxy-amino-functionalized-aromatic carboxy compounds as calcilytic compounds useful against bone and mineral diseases. Patent WO 2005077886, 2005.
29. Marquis, R. W.; Casillas, L. N.; Ramanjulu, J. M.; Callahan, J. F. Preparation of phenylalkanoic acids as calcilytic compounds. Patent WO 200404775, 2004.
30. Balan, G.; Bauman, J.; Bhattacharya, S.; Castrodad, M.; Healy, D. R.; Herr, M.; Humphries, P.; Jennings, S.; Kalgutkar, A. S.; Kapinos, B.; Khot, V.; Lazarra, K.; Li, M.; Li, Y.; Neagu, C.; Oliver, R.; Piotrowski, D. W.; Price, D.; Qi, H.; Simmons, H. A.; Southers, J.; Wei, L.; Zhang, Y.; Paralkar, V. M. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg. Med. Chem. Lett. 2009, 19 (12), 3328-3332.
31. Fitzpatrick, L. A.; Brennan, E.; Kumar, S.; Matheny, C.; Yi, B.; McLaughlin, M.; Phillips, J.; Skordos, L.; Ethgen, D. Ronacaleret, a novel calcium-sensing receptor antagonist demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. ASBMR 30th Annual Meeting, Montreal, 2008, Abstract 1174.
32. Yang, W.; Ruan, Z.; Wang, Y.; Van Kirk, K.; Ma, Z.; Arey, B. J.; Cooper, C. B.; Seethala, R.; Feyen, J. H. M.; Dickson, J. K. Discovery and structure-activity relationships of trisubstituted pyrimidines/pyridines as novel calcium-sensing receptor antagonists. J. Med. Chem. 2009, 52 (4), 1204-1208.
33. Gavai, A. V.; Vaz, R. J.; Mikkilineni, A. B.; Roberge, J. Y.; Liu, Y.; Lawrence, M; Corte, J. R.; Yang, W.; Bednarz, M.; Dickson, J. K.; Ma, Z.; Seethala, R.; Feyen, J. H. M. Discovery of novel 1-arylmethylpyrrolidin-2- ylethanolamines as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15 (24), 5478-5482.
34. Arey, B. J.; Seethala, R.; Ma, Z.; Fura, A.; Morin, J.; Swartz, J.; Vyas, V; Yang. W.; Dickson, J.; Feyen, J. H. M. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology 2005, 146 (4), 2015-2022.
35. Yang, W.; Wang, Y.; Roberge, J. Y.; Ma, Z.; Liu, Y.; Lawrence, R. M.; Rotella, D. P.; Seethala, R.; Feyen, J. H. M.; Dickson, J. K. Discovery and structure-activity relationships of 2-benzylpyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15 (4), 1225-1228.
36. 2-[1-(1-naphthyl)ethyl] -trans-l,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J. Med. Chem. 2006, 49 (17), 5119-5128.
37. l-(l-(1-naphthyl) ethyl)-3-phenylpropane-l,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2004, 14 (12), 3345-3349.
38. 2-(l-(1-naphthyl) ethyl-l,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. ChemBioChem 2004, 5 (8), 1131-1136.
39. 2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J. Biol. Chem. 2004, 279 (18), 18990-18997.
40. 2 -(1aryl)ethyl-3-phenylpropane-l,2- diamines as novel calcimimetics acting on the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2000, 10(17), 2001-2004.
41. Shcherbakova, I.; Huang, G. I.; Geoffroy, J.; Nair, S. K.; Swierczek, K.; Balandrin, M. F.; Fox, J.; Heaton, W. L.; Conklin, R. L. Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg. Med. Chem. Lett. 2005, 15 (10), 2537-2540
42. Shcherbakova, I.; Balandrin, M. F.; Fox, J.; Ghatak, A.; Heaton, W. L.; Conklin, R. L. 3H-Quinazolin-4-ones as anew calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett. 2005, 15(6), 1557-1560.
43. Shinagawa, Y.; Inoue, T.; Kiguchi, T.; Ikenogami, T.; Ogawa, N.; Fukuda, K.; Nakagawa, T.; Shindo, M.; Soejima, Y. CaSR antagonists. Patent EP 1630157, 2004.
44. Shinagawa, Y.; Inoue, T.; Kiguchi, T.; Ikenogami, T.; Ogawa, N.; Nakagawa, T.; Shindo, M.; Soejima, Y. Preparation of 3-[[2-methyl-3-aryl-2- propyl]amino]-l,2-propanediol derivatives as calcium-sensing receptor (CaSR) antagonists. Patent WO 2004106280, 2004.
45. Gabka, J. Analgesic and anti-inflammatory activity of Biarison. Clinical experimental studies. München Med. Wochen. 1978, 120 (10), 331-334.
46. Houlihan, W. J.; Cooke, G.; Van Bochoven, R.; Perrine, J.; Takesue, E. I.; Jukniewicz, E. Anti-inflammatory properties of 8-aryl-5-isopropyl-2H-1,3- dioxolo[4,5-g]quinazolin-6(5H)-ones and -thiones. J. Med. Chem. 1982, 25 (9), 1110-1113.
47. Perrine, J. W.; Houlihan, W. J.; Takesue, E. I. Anti-inflammatory and other pharmacodynamic properties of five members of the 4-aryl-1-isopropyl-2(1H) -quinazolinone series. Arzneim.-Forsch. 1984, 34 (8), 879-885.
48. Houlihan, W. J.; Cooke, G.; Denzer, M.; Nicoletti, J. 1-Alkyl-4-aryl-3,4-dihydro-2(lH)-quinazolinones and thiones. Synthesis and proton-NMR spectra. J. Heterocycl. Chem. 1982, 19 (6), 1453-1456.
49. Wohnsland, F.; Faller, B. High throughput permeability pH profile and High throughput alkane/water log P with artificial membranes. J. Med. Chem. 2001, 44, 923-930.
50. 2+-sensing receptor. J. Biol. Chem. 2003, 278, 49487-49494.
51. Miedlich, S. U.; Gama, L.; Seuwen, K.; Wolf, R. M.; Breitwieser, G. E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 2004, 279, 7254-7263.
52. 2+sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J. Biol. Chem. 2004, 279, 18990-18997.
53. Bu, L.; Michino, M.; Wolf, R. M.; Brooks, C. L. Improved model building and assessment of the calcium-sensing receptor transmembrane domain. Proteins. 2008, 71, 215-226.
54. Seuwen, K.; Halleux, C.; Bouhelal, R.; Kneissel, M.; Buhl, T.; Gamse, R.; Wolf, R. M.; Breitwieser, G.; Beerli, R.; Weiler, S.; Widler, L. A new class of noncompetitive antagonists of the human calcium-sensing receptor releasing parathyroid hormone (PTH) from parathyroid glands. Poster presented at the 26th Annual Meeting of the American Society of Bone and Mineral Research (ASBMR), Seattle, WA, 2004.
55. DeLano, W. L. The PyMOL Molecular Graphics System, version 1.0r2; DeLano Scientific LLC: San Carlos, CA; http://www.pymol.org.
56. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem. 2003, 24, 1999-2012.
57. Wang, J.;Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25, 1157-1174.
58. See, e.g., Lennernaes, H.; Abrahamsson, B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 2005, 57 (3), 273-285.
59. Bowden, K.; Heilbron, I. M.; Jones, E. R. H.; Weedon, B. C. L. Acetylenic compounds. I. Preparation of acetylenic ketones by oxidation of acetylenic carbinols and glycols. J. Chem. Soc. 1946, 39-45.